Dawn Carter Bir is CCO at REATA PHARMACEUTICALS INC (RETA). They have made 6 open-market trades across 1 company since 2020, most recently 2025-06-05.
CIK 0001688712
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 6 sales. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| RETA | SELL | 2023-08-15 | 2023-08-17 | $168.81 | $407K | -0.1% | +1.8% | N/A |
| RETA | SELL · 10b5-1 | 2023-07-28 | 2023-08-01 | $164.54 | $6.6M | +0.9% | +1.8% | N/A |
| RETA | SELL | 2023-05-15 | 2023-05-17 | $84.31 | $186K | +10.2% | +14.7% | +107.8% |
| RETA | SELL | 2023-03-13 | 2023-03-15 | $86.77 | $1.6M | +4.5% | +11.6% | +23.1% |
| RETA | SELL | 2023-03-06 | 2023-03-08 | $87.67 | $17.0M | +9.4% | +15.0% | +15.0% |
| RETA | SELL | 2023-03-03 | 2023-03-06 | $88.25 | $382K | +2.8% | +6.0% | +5.3% |
| RETA | SELL | 2020-11-09 | 2020-11-10 | $162.51 | $9.8M | -11.5% | -32.6% | -38.3% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.